What is the projected market valuation for the Targeted Cancer Therapies Market by 2035?

The projected market valuation for the Targeted Cancer Therapies Market is 912.18 USD Billion by 2035. Read More

What was the overall market valuation for the Targeted Cancer Therapies Market in 2024?

The overall market valuation for the Targeted Cancer Therapies Market was 303.49 USD Billion in 2024. Read More

What is the expected CAGR for the Targeted Cancer Therapies Market during the forecast period 2025 - 2035?

The expected CAGR for the Targeted Cancer Therapies Market during the forecast period 2025 - 2035 is 10.52%. Read More

Which companies are considered key players in the Targeted Cancer Therapies Market?

Key players in the Targeted Cancer Therapies Market include Roche, Novartis, Bristol-Myers Squibb, Merck & Co., Pfizer, AstraZeneca, Gilead Sciences, Amgen, and Eli Lilly and Company. Read More

What segment of the Targeted Cancer Therapies Market had the highest valuation in 2024?

In 2024, the segment of Targeted Antibody Therapies had the highest valuation at 80.0 USD Billion. Read More

How does the market valuation for Lung Cancer therapies compare to that for Breast Cancer therapies in 2024?

In 2024, the market valuation for Lung Cancer therapies was 60.0 USD Billion, while Breast Cancer therapies had a valuation of 70.0 USD Billion. Read More

What is the projected market size for Targeted Protein Inhibitors by 2035?

The projected market size for Targeted Protein Inhibitors is expected to reach 180.0 USD Billion by 2035. Read More

Which administration route for targeted cancer therapies had the highest valuation in 2024?

The Intravenous administration route for targeted cancer therapies had the highest valuation at 120.0 USD Billion in 2024. Read More

What is the market valuation for Immunoconjugates in 2024?

The market valuation for Immunoconjugates was 83.49 USD Billion in 2024. Read More

Which biomarker expression segment is projected to grow the most by 2035?

The EGFR biomarker expression segment is projected to grow significantly, reaching 180.0 USD Billion by 2035. Read More

Targeted Cancer Therapies Market

ID: MRFR/HC/26208-HCR

100 Pages

Rahul Gotadki

Last Updated: April 24, 2026

Targeted Cancer Therapies Market Research Report: Size, Share, Trend Analysis By Types (Targeted Protein Inhibitors, Targeted Antibody Therapies, Targeted Cancer Vaccines, Hormone Therapy, Immunoconjugates), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Lymphoma, Melanoma, Non-Hodgkin Lymphoma), By Administration Route (Oral, Intravenous, Subcutaneous, Intraperitoneal), By Biomarker Expression (KRAS, EGFR, ALK, BRAF, HER2), By Targeted Mechanism (Cell Cycle Inhibition, Epigenetic Modification, Angiogenesis Inhibition, Immunomodulation, DNA Repair Inhibition) By Regional - Forecast to 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Billion)
  1. 4.1.1 Targeted Protein Inhibitors
  2. 4.1.2 Targeted Antibody Therapies
  3. 4.1.3 Targeted Cancer Vaccines
  4. 4.1.4 Hormone Therapy
  5. 4.1.5 Immunoconjugates
2. 4.2 Healthcare, BY Cancer Type (USD Billion)
  1. 4.2.1 Lung Cancer
  2. 4.2.2 Breast Cancer
  3. 4.2.3 Colorectal Cancer
  4. 4.2.4 Prostate Cancer
  5. 4.2.5 Leukemia
  6. 4.2.6 Lymphoma
  7. 4.2.7 Melanoma
  8. 4.2.8 Non-Hodgkin Lymphoma
3. 4.3 Healthcare, BY Administration Route (USD Billion)
  1. 4.3.1 Oral
  2. 4.3.2 Intravenous
  3. 4.3.3 Subcutaneous
  4. 4.3.4 Intraperitoneal
4. 4.4 Healthcare, BY Biomarker Expression (USD Billion)
  1. 4.4.1 KRAS
  2. 4.4.2 EGFR
  3. 4.4.3 ALK
  4. 4.4.4 BRAF
  5. 4.4.5 HER2
5. 4.5 Healthcare, BY Targeted Mechanism (USD Billion)
  1. 4.5.1 Cell Cycle Inhibition
  2. 4.5.2 Epigenetic Modification
  3. 4.5.3 Angiogenesis Inhibition
  4. 4.5.4 Immunomodulation
  5. 4.5.5 DNA Repair Inhibition
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck & Co. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Gilead Sciences (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Eli Lilly and Company (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY CANCER TYPE
5. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
6. 6.6 US MARKET ANALYSIS BY BIOMARKER EXPRESSION
7. 6.7 US MARKET ANALYSIS BY TARGETED MECHANISM
8. 6.8 CANADA MARKET ANALYSIS BY TYPE
9. 6.9 CANADA MARKET ANALYSIS BY CANCER TYPE
10. 6.10 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
11. 6.11 CANADA MARKET ANALYSIS BY BIOMARKER EXPRESSION
12. 6.12 CANADA MARKET ANALYSIS BY TARGETED MECHANISM
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY CANCER TYPE
16. 6.16 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
17. 6.17 GERMANY MARKET ANALYSIS BY BIOMARKER EXPRESSION
18. 6.18 GERMANY MARKET ANALYSIS BY TARGETED MECHANISM
19. 6.19 UK MARKET ANALYSIS BY TYPE
20. 6.20 UK MARKET ANALYSIS BY CANCER TYPE
21. 6.21 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
22. 6.22 UK MARKET ANALYSIS BY BIOMARKER EXPRESSION
23. 6.23 UK MARKET ANALYSIS BY TARGETED MECHANISM
24. 6.24 FRANCE MARKET ANALYSIS BY TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY CANCER TYPE
26. 6.26 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
27. 6.27 FRANCE MARKET ANALYSIS BY BIOMARKER EXPRESSION
28. 6.28 FRANCE MARKET ANALYSIS BY TARGETED MECHANISM
29. 6.29 RUSSIA MARKET ANALYSIS BY TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY CANCER TYPE
31. 6.31 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
32. 6.32 RUSSIA MARKET ANALYSIS BY BIOMARKER EXPRESSION
33. 6.33 RUSSIA MARKET ANALYSIS BY TARGETED MECHANISM
34. 6.34 ITALY MARKET ANALYSIS BY TYPE
35. 6.35 ITALY MARKET ANALYSIS BY CANCER TYPE
36. 6.36 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
37. 6.37 ITALY MARKET ANALYSIS BY BIOMARKER EXPRESSION
38. 6.38 ITALY MARKET ANALYSIS BY TARGETED MECHANISM
39. 6.39 SPAIN MARKET ANALYSIS BY TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY CANCER TYPE
41. 6.41 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
42. 6.42 SPAIN MARKET ANALYSIS BY BIOMARKER EXPRESSION
43. 6.43 SPAIN MARKET ANALYSIS BY TARGETED MECHANISM
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY CANCER TYPE
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY BIOMARKER EXPRESSION
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY TARGETED MECHANISM
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TYPE
51. 6.51 CHINA MARKET ANALYSIS BY CANCER TYPE
52. 6.52 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
53. 6.53 CHINA MARKET ANALYSIS BY BIOMARKER EXPRESSION
54. 6.54 CHINA MARKET ANALYSIS BY TARGETED MECHANISM
55. 6.55 INDIA MARKET ANALYSIS BY TYPE
56. 6.56 INDIA MARKET ANALYSIS BY CANCER TYPE
57. 6.57 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
58. 6.58 INDIA MARKET ANALYSIS BY BIOMARKER EXPRESSION
59. 6.59 INDIA MARKET ANALYSIS BY TARGETED MECHANISM
60. 6.60 JAPAN MARKET ANALYSIS BY TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY CANCER TYPE
62. 6.62 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
63. 6.63 JAPAN MARKET ANALYSIS BY BIOMARKER EXPRESSION
64. 6.64 JAPAN MARKET ANALYSIS BY TARGETED MECHANISM
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY CANCER TYPE
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY BIOMARKER EXPRESSION
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY TARGETED MECHANISM
70. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY CANCER TYPE
72. 6.72 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
73. 6.73 MALAYSIA MARKET ANALYSIS BY BIOMARKER EXPRESSION
74. 6.74 MALAYSIA MARKET ANALYSIS BY TARGETED MECHANISM
75. 6.75 THAILAND MARKET ANALYSIS BY TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY CANCER TYPE
77. 6.77 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
78. 6.78 THAILAND MARKET ANALYSIS BY BIOMARKER EXPRESSION
79. 6.79 THAILAND MARKET ANALYSIS BY TARGETED MECHANISM
80. 6.80 INDONESIA MARKET ANALYSIS BY TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY CANCER TYPE
82. 6.82 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
83. 6.83 INDONESIA MARKET ANALYSIS BY BIOMARKER EXPRESSION
84. 6.84 INDONESIA MARKET ANALYSIS BY TARGETED MECHANISM
85. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY CANCER TYPE
87. 6.87 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
88. 6.88 REST OF APAC MARKET ANALYSIS BY BIOMARKER EXPRESSION
89. 6.89 REST OF APAC MARKET ANALYSIS BY TARGETED MECHANISM
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY CANCER TYPE
93. 6.93 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
94. 6.94 BRAZIL MARKET ANALYSIS BY BIOMARKER EXPRESSION
95. 6.95 BRAZIL MARKET ANALYSIS BY TARGETED MECHANISM
96. 6.96 MEXICO MARKET ANALYSIS BY TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY CANCER TYPE
98. 6.98 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
99. 6.99 MEXICO MARKET ANALYSIS BY BIOMARKER EXPRESSION
100. 6.100 MEXICO MARKET ANALYSIS BY TARGETED MECHANISM
101. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY CANCER TYPE
103. 6.103 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
104. 6.104 ARGENTINA MARKET ANALYSIS BY BIOMARKER EXPRESSION
105. 6.105 ARGENTINA MARKET ANALYSIS BY TARGETED MECHANISM
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY CANCER TYPE
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY BIOMARKER EXPRESSION
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGETED MECHANISM
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY CANCER TYPE
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY BIOMARKER EXPRESSION
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY TARGETED MECHANISM
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY CANCER TYPE
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY BIOMARKER EXPRESSION
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY TARGETED MECHANISM
122. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY CANCER TYPE
124. 6.124 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
125. 6.125 REST OF MEA MARKET ANALYSIS BY BIOMARKER EXPRESSION
126. 6.126 REST OF MEA MARKET ANALYSIS BY TARGETED MECHANISM
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY CANCER TYPE, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY CANCER TYPE, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY BIOMARKER EXPRESSION, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY BIOMARKER EXPRESSION, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY TARGETED MECHANISM, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY TARGETED MECHANISM, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.2.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.2.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.3.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.3.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.4.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.4.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.5.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.5.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.6.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.6.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.7.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.7.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.8.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.8.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.9.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.9.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.10.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.10.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.11.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.11.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.12.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.12.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.13.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.13.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.14.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.14.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.15.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.15.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.16.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.16.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.17.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.17.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.18.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.18.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.19.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.19.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.20.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.20.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.21.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.21.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.22.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.22.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.23.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.23.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.24.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.24.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.25.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.25.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.26.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.26.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.27.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.27.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.28.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.28.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.29.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.29.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.30.4 BY BIOMARKER EXPRESSION, 2025-2035 (USD Billion)
  5. 7.30.5 BY TARGETED MECHANISM, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Targeted Cancer Therapies Market Segmentation

Targeted Cancer Therapies Market By Type (USD Billion, 2025-2035)

Targeted Protein Inhibitors
Targeted Antibody Therapies
Targeted Cancer Vaccines
Hormone Therapy
Immunoconjugates

Targeted Cancer Therapies Market By Cancer Type (USD Billion, 2025-2035)

Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Leukemia
Lymphoma
Melanoma
Non-Hodgkin Lymphoma

Targeted Cancer Therapies Market By Administration Route (USD Billion, 2025-2035)

Oral
Intravenous
Subcutaneous
Intraperitoneal

Targeted Cancer Therapies Market By Biomarker Expression (USD Billion, 2025-2035)

KRAS
EGFR
ALK
BRAF
HER2

Targeted Cancer Therapies Market By Targeted Mechanism (USD Billion, 2025-2035)

Cell Cycle Inhibition
Epigenetic Modification
Angiogenesis Inhibition
Immunomodulation
DNA Repair Inhibition

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”